AGRX Insider Trading Activity and SEC Form 4 Filings
AGRX insider trading summary
No open-market insider purchases or sales of Agile Therapeutics Inc (AGRX) have been reported on SEC Form 4 in the past 12 months.
Latest AGRX insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Aug 26, 2022 | Alfred Altomari | Chief Executive Officer | Buy | $23K (50,000 @ $0.45) |
| Oct 13, 2021 | Perceptive Advisors LLC | 10% Owner | Buy | $4.9M (5,734,560 @ $0.85) |
| Oct 13, 2021 | Perceptive Life Sciences Master Fund Ltd | 10% Owner | Buy | $4.9M (5,734,560 @ $0.85) |
| Oct 13, 2021 | Joseph Edelman | 10% Owner | Buy | $4.9M (5,734,560 @ $0.85) |
| Oct 13, 2021 | Alfred Altomari | Chief Executive Officer | Buy | $0 (58,824 @ $0.00) |
| Oct 13, 2021 | Dennis Reilly | Chief Financial Officer | Buy | $0 (58,824 @ $0.00) |
| Jul 29, 2021 | Alfred Altomari | Chief Executive Officer | Buy | $33K (26,200 @ $1.26) |
| Jul 27, 2021 | Dennis Reilly | Chief Financial Officer | Buy | $54K (50,000 @ $1.08) |
| May 18, 2021 | Alfred Altomari | Chief Executive Officer | Buy | $32K (20,000 @ $1.61) |
| May 11, 2021 | Dennis Reilly | Chief Financial Officer | Buy | $27K (20,000 @ $1.35) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.